Lichen International Ltd LICN
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-4.11
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $24.5M | $41.5M | $39.8M | $33.8M | $34.3M | $23.3M | — |
| Cost of revenue | $15.4M | $15.8M | $15.4M | $13.6M | $13.8M | $11.8M | — |
| Gross profit | $9.1M | $25.7M | $24.3M | $20.2M | $20.5M | $18.8M | — |
| SG&A | $12.9M | $17.7M | $8.9M | $7.4M | $7.2M | $8.5M | — |
| Total operating expenses | $27.2M | $30.2M | $12.1M | $9.5M | $9.2M | $10.0M | — |
| Operating income | -$18.1M | -$4.6M | $12.3M | $10.6M | $11.3M | $8.8M | — |
| Pre-tax income | -$21.8M | -$4.2M | $11.6M | $10.7M | $11.5M | $9.0M | — |
| Income tax | $0 | $1.9M | $3.2M | $2.9M | $3.1M | $2.6M | — |
| Net income | -$22.0M | -$6.1M | $8.3M | $7.8M | $8.5M | $6.4M | — |
| EPS, basic | -4.11 | -34.79 | 63.96 | 69.50 | 0.38 | 0.28 | — |
| EPS, diluted | -4.11 | -34.79 | 63.96 | 69.50 | 0.38 | 0.28 | — |
| Shares, diluted (wtd. avg.) | 5.3M | 175,897 | 130,363 | 112,500 | 22.5M | 22.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $26.9M | $26.7M | $25.9M | $22.6M | $16.8M | $8.7M | $5.4M |
| Receivables | — | — | $4.5M | $3.5M | $419.0K | — | — |
| Inventory | $0 | $67.0K | $87.0K | $127.0K | $150.0K | — | — |
| Total current assets | $36.2M | $34.0M | $40.1M | $27.3M | $23.9M | — | — |
| Property, plant and equipment | $7.0M | $13.7M | $14.6M | $13.3M | $14.9M | — | — |
| Goodwill | $791.0K | $4.5M | $0 | — | — | — | — |
| Other intangibles | $8.1M | $11.1M | $6.0M | $4.5M | $3.9M | — | — |
| Total assets | $75.6M | $79.8M | $65.5M | $46.5M | $42.9M | — | — |
| Accounts payable | $0 | $55.0K | $61.0K | $161.0K | $123.0K | — | — |
| Short-term debt | — | — | $1.6M | $1.1M | $345.0K | — | — |
| Total current liabilities | $4.7M | $4.3M | $4.1M | $5.2M | $6.1M | — | — |
| Total liabilities | $5.0M | $4.3M | $4.1M | $5.4M | — | — | — |
| Retained earnings | $20.1M | $42.1M | $48.2M | $40.8M | $33.0M | — | — |
| Total equity | $70.5M | $73.2M | $61.4M | $41.1M | $36.8M | $27.6M | $23.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.8M | -$5.6M | $557.0K | $10.8M | $7.3M | $8.3M | — |
| Depreciation and amortisation | $561.0K | $691.0K | $681.0K | $651.0K | $660.0K | $719.0K | — |
| Stock-based compensation | $314.0K | $3.4M | $0 | — | — | — | — |
| Capital expenditure | $0 | $36.0K | $3.2M | $1.9M | $28.0K | — | — |
| Investing cash flow | -$5.5M | -$9.9M | -$9.9M | -$2.8M | $561.0K | -$1.2M | — |
| Financing cash flow | $23.6M | $13.1M | $14.1M | -$327.0K | — | -$4.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001185185-26-001520.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $23.3M | $34.3M | $33.8M | $39.8M | $41.5M | $24.5M |
| Gross profit | — | $18.8M | $20.5M | $20.2M | $24.3M | $25.7M | $9.1M |
| Net income | — | $6.4M | $8.5M | $7.8M | $8.3M | -$6.1M | -$22.0M |
Others in SIC 8742
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BAH | Booz Allen Hamilton Holding Corp | $9.42B | 11.4x | -6.4% |
| G | Genpact LTD | $6.86B | 13.0x | 6.6% |
| FCN | FTI CONSULTING, INC | $4.34B | 19.1x | 2.4% |
| EXPO | EXPONENT INC | $3.68B | 37.4x | 4.2% |
| HURN | Huron Consulting Group Inc. | $3.17B | 33.5x | 11.9% |
| ASTH | Astrana Health, Inc. | $2.09B | 81.4x | 56.4% |
| ICFI | ICF International, Inc. | $1.69B | 19.1x | -7.3% |
| BWMN | Bowman Consulting Group Ltd. | $742.5M | 58.7x | 14.9% |